Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors

Cristina Alencar, Matthew Abramowtiz, Samir Parekh, Ira Braunshweig, Mark Jacobson, Lewis Silverman, Amit K. Verma

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Epigenetic silencing of tumor suppressors is seen in Myelodysplastic Syndrome (MDS) and even though demethylating agents have improved survival in this disease, a majority of patients are still resistant to these therapies. In an effort to improve response rates, newer combinations of histone deacetylase (HDAC) inhibitors and hypomethylating agents are being used to reverse aberrant epigenetic silencing in MDS. The combinations of these agents may result in unanticipated toxicities. We report three cases of Sweet's syndrome (SS) associated with the use of 5-Azacitidine/Decitabine in combination with HDAC inhibition. They were characterized by atypical pathological appearance with relatively lesser number of invading neutrophils, presumably because of the underlying bone marrow failure. One case was characterized by fulminant and aggressive nature of SS, which became refractory to standard immunosuppressive treatments and result in mortality. SS should thus be considered a part of differential diagnosis of skin lesions in patients receiving combination of epigenetic therapies and should be treated aggressively.

Original languageEnglish (US)
Pages (from-to)688-689
Number of pages2
JournalAmerican Journal of Hematology
Volume84
Issue number10
DOIs
StatePublished - Oct 2009

Fingerprint

Sweet Syndrome
Histone Deacetylase Inhibitors
Myelodysplastic Syndromes
Epigenomics
decitabine
Azacitidine
Histone Deacetylases
Immunosuppressive Agents
Neutrophils
Differential Diagnosis
Therapeutics
Bone Marrow
Skin
Survival
Mortality
Neoplasms

ASJC Scopus subject areas

  • Hematology

Cite this

Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors. / Alencar, Cristina; Abramowtiz, Matthew; Parekh, Samir; Braunshweig, Ira; Jacobson, Mark; Silverman, Lewis; Verma, Amit K.

In: American Journal of Hematology, Vol. 84, No. 10, 10.2009, p. 688-689.

Research output: Contribution to journalArticle

Alencar, Cristina ; Abramowtiz, Matthew ; Parekh, Samir ; Braunshweig, Ira ; Jacobson, Mark ; Silverman, Lewis ; Verma, Amit K. / Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors. In: American Journal of Hematology. 2009 ; Vol. 84, No. 10. pp. 688-689.
@article{f72f30eefdf24571a86cba5625b9696e,
title = "Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors",
abstract = "Epigenetic silencing of tumor suppressors is seen in Myelodysplastic Syndrome (MDS) and even though demethylating agents have improved survival in this disease, a majority of patients are still resistant to these therapies. In an effort to improve response rates, newer combinations of histone deacetylase (HDAC) inhibitors and hypomethylating agents are being used to reverse aberrant epigenetic silencing in MDS. The combinations of these agents may result in unanticipated toxicities. We report three cases of Sweet's syndrome (SS) associated with the use of 5-Azacitidine/Decitabine in combination with HDAC inhibition. They were characterized by atypical pathological appearance with relatively lesser number of invading neutrophils, presumably because of the underlying bone marrow failure. One case was characterized by fulminant and aggressive nature of SS, which became refractory to standard immunosuppressive treatments and result in mortality. SS should thus be considered a part of differential diagnosis of skin lesions in patients receiving combination of epigenetic therapies and should be treated aggressively.",
author = "Cristina Alencar and Matthew Abramowtiz and Samir Parekh and Ira Braunshweig and Mark Jacobson and Lewis Silverman and Verma, {Amit K.}",
year = "2009",
month = "10",
doi = "10.1002/ajh.21510",
language = "English (US)",
volume = "84",
pages = "688--689",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "10",

}

TY - JOUR

T1 - Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors

AU - Alencar, Cristina

AU - Abramowtiz, Matthew

AU - Parekh, Samir

AU - Braunshweig, Ira

AU - Jacobson, Mark

AU - Silverman, Lewis

AU - Verma, Amit K.

PY - 2009/10

Y1 - 2009/10

N2 - Epigenetic silencing of tumor suppressors is seen in Myelodysplastic Syndrome (MDS) and even though demethylating agents have improved survival in this disease, a majority of patients are still resistant to these therapies. In an effort to improve response rates, newer combinations of histone deacetylase (HDAC) inhibitors and hypomethylating agents are being used to reverse aberrant epigenetic silencing in MDS. The combinations of these agents may result in unanticipated toxicities. We report three cases of Sweet's syndrome (SS) associated with the use of 5-Azacitidine/Decitabine in combination with HDAC inhibition. They were characterized by atypical pathological appearance with relatively lesser number of invading neutrophils, presumably because of the underlying bone marrow failure. One case was characterized by fulminant and aggressive nature of SS, which became refractory to standard immunosuppressive treatments and result in mortality. SS should thus be considered a part of differential diagnosis of skin lesions in patients receiving combination of epigenetic therapies and should be treated aggressively.

AB - Epigenetic silencing of tumor suppressors is seen in Myelodysplastic Syndrome (MDS) and even though demethylating agents have improved survival in this disease, a majority of patients are still resistant to these therapies. In an effort to improve response rates, newer combinations of histone deacetylase (HDAC) inhibitors and hypomethylating agents are being used to reverse aberrant epigenetic silencing in MDS. The combinations of these agents may result in unanticipated toxicities. We report three cases of Sweet's syndrome (SS) associated with the use of 5-Azacitidine/Decitabine in combination with HDAC inhibition. They were characterized by atypical pathological appearance with relatively lesser number of invading neutrophils, presumably because of the underlying bone marrow failure. One case was characterized by fulminant and aggressive nature of SS, which became refractory to standard immunosuppressive treatments and result in mortality. SS should thus be considered a part of differential diagnosis of skin lesions in patients receiving combination of epigenetic therapies and should be treated aggressively.

UR - http://www.scopus.com/inward/record.url?scp=70349502129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349502129&partnerID=8YFLogxK

U2 - 10.1002/ajh.21510

DO - 10.1002/ajh.21510

M3 - Article

C2 - 19722261

AN - SCOPUS:70349502129

VL - 84

SP - 688

EP - 689

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 10

ER -